Copyright Reports & Markets. All rights reserved.

Global and China Lysosomal Storage Disease (LSD) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Lipid Metabolism Disorder
    • 1.2.3 Glycoprotein Metabolism Disorder
  • 1.3 Market by Application
    • 1.3.1 Global Lysosomal Storage Disease (LSD) Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Lysosomal Storage Disease (LSD) Market Perspective (2015-2026)
  • 2.2 Global Lysosomal Storage Disease (LSD) Growth Trends by Regions
    • 2.2.1 Lysosomal Storage Disease (LSD) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Lysosomal Storage Disease (LSD) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Lysosomal Storage Disease (LSD) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Lysosomal Storage Disease (LSD) Players by Market Size
    • 3.1.1 Global Top Lysosomal Storage Disease (LSD) Players by Revenue (2015-2020)
    • 3.1.2 Global Lysosomal Storage Disease (LSD) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Lysosomal Storage Disease (LSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Lysosomal Storage Disease (LSD) Revenue
  • 3.4 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio
    • 3.4.1 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Disease (LSD) Revenue in 2019
  • 3.5 Key Players Lysosomal Storage Disease (LSD) Area Served
  • 3.6 Key Players Lysosomal Storage Disease (LSD) Product Solution and Service
  • 3.7 Date of Enter into Lysosomal Storage Disease (LSD) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Lysosomal Storage Disease (LSD) Breakdown Data by Type (2015-2026)

  • 4.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Type (2015-2020)
  • 4.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2021-2026)

5 Lysosomal Storage Disease (LSD) Breakdown Data by Application (2015-2026)

  • 5.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Application (2015-2020)
  • 5.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Lysosomal Storage Disease (LSD) Market Size (2015-2026)
  • 6.2 North America Lysosomal Storage Disease (LSD) Market Size by Type (2015-2020)
  • 6.3 North America Lysosomal Storage Disease (LSD) Market Size by Application (2015-2020)
  • 6.4 North America Lysosomal Storage Disease (LSD) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Lysosomal Storage Disease (LSD) Market Size (2015-2026)
  • 7.2 Europe Lysosomal Storage Disease (LSD) Market Size by Type (2015-2020)
  • 7.3 Europe Lysosomal Storage Disease (LSD) Market Size by Application (2015-2020)
  • 7.4 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Lysosomal Storage Disease (LSD) Market Size (2015-2026)
  • 8.2 China Lysosomal Storage Disease (LSD) Market Size by Type (2015-2020)
  • 8.3 China Lysosomal Storage Disease (LSD) Market Size by Application (2015-2020)
  • 8.4 China Lysosomal Storage Disease (LSD) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Lysosomal Storage Disease (LSD) Market Size (2015-2026)
  • 9.2 Japan Lysosomal Storage Disease (LSD) Market Size by Type (2015-2020)
  • 9.3 Japan Lysosomal Storage Disease (LSD) Market Size by Application (2015-2020)
  • 9.4 Japan Lysosomal Storage Disease (LSD) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Lysosomal Storage Disease (LSD) Market Size (2015-2026)
  • 10.2 Southeast Asia Lysosomal Storage Disease (LSD) Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Lysosomal Storage Disease (LSD) Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Lysosomal Storage Disease (LSD) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Actelion Pharmaceuticals
    • 11.1.1 Actelion Pharmaceuticals Company Details
    • 11.1.2 Actelion Pharmaceuticals Business Overview
    • 11.1.3 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
    • 11.1.4 Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020))
    • 11.1.5 Actelion Pharmaceuticals Recent Development
  • 11.2 Amicus Therapeutics
    • 11.2.1 Amicus Therapeutics Company Details
    • 11.2.2 Amicus Therapeutics Business Overview
    • 11.2.3 Amicus Therapeutics Lysosomal Storage Disease (LSD) Introduction
    • 11.2.4 Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.2.5 Amicus Therapeutics Recent Development
  • 11.3 Arena Pharmaceuticals
    • 11.3.1 Arena Pharmaceuticals Company Details
    • 11.3.2 Arena Pharmaceuticals Business Overview
    • 11.3.3 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
    • 11.3.4 Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.3.5 Arena Pharmaceuticals Recent Development
  • 11.4 Astellas Pharma
    • 11.4.1 Astellas Pharma Company Details
    • 11.4.2 Astellas Pharma Business Overview
    • 11.4.3 Astellas Pharma Lysosomal Storage Disease (LSD) Introduction
    • 11.4.4 Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.4.5 Astellas Pharma Recent Development
  • 11.5 Astrazeneca
    • 11.5.1 Astrazeneca Company Details
    • 11.5.2 Astrazeneca Business Overview
    • 11.5.3 Astrazeneca Lysosomal Storage Disease (LSD) Introduction
    • 11.5.4 Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.5.5 Astrazeneca Recent Development
  • 11.6 Biomarin Pharmaceutical
    • 11.6.1 Biomarin Pharmaceutical Company Details
    • 11.6.2 Biomarin Pharmaceutical Business Overview
    • 11.6.3 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Introduction
    • 11.6.4 Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.6.5 Biomarin Pharmaceutical Recent Development
  • 11.7 Eli Lilly
    • 11.7.1 Eli Lilly Company Details
    • 11.7.2 Eli Lilly Business Overview
    • 11.7.3 Eli Lilly Lysosomal Storage Disease (LSD) Introduction
    • 11.7.4 Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.7.5 Eli Lilly Recent Development
  • 11.8 Lexicon Pharmaceuticals
    • 11.8.1 Lexicon Pharmaceuticals Company Details
    • 11.8.2 Lexicon Pharmaceuticals Business Overview
    • 11.8.3 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
    • 11.8.4 Lexicon Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.8.5 Lexicon Pharmaceuticals Recent Development
  • 11.9 Novo Nordisk
    • 11.9.1 Novo Nordisk Company Details
    • 11.9.2 Novo Nordisk Business Overview
    • 11.9.3 Novo Nordisk Lysosomal Storage Disease (LSD) Introduction
    • 11.9.4 Novo Nordisk Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.9.5 Novo Nordisk Recent Development
  • 11.10 Merck
    • 11.10.1 Merck Company Details
    • 11.10.2 Merck Business Overview
    • 11.10.3 Merck Lysosomal Storage Disease (LSD) Introduction
    • 11.10.4 Merck Revenue in Lysosomal Storage Disease (LSD) Business (2015-2020)
    • 11.10.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Lysosomal Storage Disease (LSD) Scope and Market Size
    Lysosomal Storage Disease (LSD) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Lysosomal Storage Disease (LSD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Lipid Metabolism Disorder
    Glycoprotein Metabolism Disorder

    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Based on regional and country-level analysis, the Lysosomal Storage Disease (LSD) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Lysosomal Storage Disease (LSD) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Actelion Pharmaceuticals
    Amicus Therapeutics
    Arena Pharmaceuticals
    Astellas Pharma
    Astrazeneca
    Biomarin Pharmaceutical
    Eli Lilly
    Lexicon Pharmaceuticals
    Novo Nordisk
    Merck

    Buy now